![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Patients With Human
Immunodeficiency Virus (HIV)-1 Infection: Age, Race/Ethnicity, and Gender Subgroup Analyses From the DIAMOND Study
|
|
|
17th EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
David Anderson,1,* Robert Bolan,2 Edwin DeJesus,3 Jose Guillermo Castro,4 Richard Bruce Simonson,1 Patricia Cosler,1 Sareh Seyedkazemi,1 Donghan Luo,5 Keith Dunn1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Los Angeles LGBT Center, Los Angeles, CA, USA; 3Orlando Immunology Center, Orlando, FL, USA; 4University of Miami, Miami, FL, USA; 5Janssen Research & Development, LLC, Titusville, NJ, USA
![1114191](../images/111519/111419-6/1114191.gif)
![1114192](../images/111519/111419-6/1114192.gif)
![1114193](../images/111519/111419-6/1114193.gif)
![1114194](../images/111519/111419-6/1114194.gif)
![1114195](../images/111519/111419-6/1114195.gif)
![1114196](../images/111519/111419-6/1114196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|